Anula Jayasuriya MD, PhD, MBA
Board Chair & Independent Board Member
Anula Jayasuriya is a successful venture capitalist whose background combines deep business, scientific and medical knowledge with broad clinical, industry, entrepreneurial, and investment experience. Anula founded EXXclaim Capital, an early-stage venture fund focused on catalyzing innovation, entrepreneurship and investment in Women’s Health, and co-founded EILSF, the first Indian fund focusing health care. She sits on several private biotech boards and on the board of the public company, LCTX. Previously, Anula was an investor at Skyline Ventures and TVM, VP Business Development at Genomics Collaborative Inc., and Vice President, Global Drug Development at Hoffman-La Roche. Anula received her BA from Harvard summa cum laude, and an MD and PhD from Harvard Medical School. She interned in Pediatrics at Boston Children’s Hospital and earned an MBA with distinction from Harvard Business School.
Statement: “I am extremely excited about Aarvik because of the excellent team, the superb scientific advisors and their promising next-gen Next-Gen Antibody Engineering platform that can cater function blocking antibodies, ADCs, T cell engages and beyond! These engineered antibody-based precision medicines could save/ improve the lives of cancer patients”.